Menlo Park, California, October 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, will present clinical data for its lead therapeutic compound, TVB-2640, in a late-breaking oral session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 18 – 21, 2014, in Barcelona, Spain.
TVB-2640 is an oral, proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors. FASN, an enzyme responsible for the synthesis of palmitic acid, has a key role in tumor metabolism, lipid signaling and tumor cell survival. Data from 3-V’s Phase 1 clinical trial of TV-2640 will be presented for the first time at the EORTC-NCI-AACR 2014 meeting.
Plenary Session 3: Oncolytic Viruses
November 19, 2014 at 5:20 pm
LATE BREAKING ABSTRACT: “Initial Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640”
Presenting Author: Jeffrey Infante, M.D., Sarah Cannon Research Institute in Nashville, TN.
FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. 3-V researchers will also present data in a poster session from preclinical studies supporting the potential of a biomarker for identifying tumors most likely to respond to FASN inhibition.
November 21, 2014
Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications (Abstract #591)
Presenting Author: Timothy Heuer, Ph.D., Senior Director, 3-V Biosciences
About 3-V Biosciences
3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company’s lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V’s antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
# # #
Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman